300573 兴齐眼药
已收盘 12-19 15:00:00
资讯
新帖
简况
兴齐眼药：公司持续聚焦眼科领域，坚持专业化发展道路，暂无眼科相关的医疗器械研发、生产和销售
证券之星 · 12-18 20:00
兴齐眼药：公司持续聚焦眼科领域，坚持专业化发展道路，暂无眼科相关的医疗器械研发、生产和销售
兴齐眼药（300573）12月16日主力资金净卖出1.20亿元
证券之星 · 12-17 09:23
兴齐眼药（300573）12月16日主力资金净卖出1.20亿元
兴齐眼药：12月6日接受机构调研，北京博润银泰、明世伙伴等多家机构参与
证券之星 · 12-06
兴齐眼药：12月6日接受机构调研，北京博润银泰、明世伙伴等多家机构参与
【机构调研记录】永赢基金调研兴齐眼药、新锐股份等15只个股（附名单）
证券之星 · 12-02
【机构调研记录】永赢基金调研兴齐眼药、新锐股份等15只个股（附名单）
【机构调研记录】国海富兰克林基金调研兴齐眼药、科达制造
证券之星 · 12-02
【机构调研记录】国海富兰克林基金调研兴齐眼药、科达制造
【机构调研记录】前海开源基金调研兴齐眼药、肇民科技等3只个股（附名单）
证券之星 · 12-02
【机构调研记录】前海开源基金调研兴齐眼药、肇民科技等3只个股（附名单）
兴齐眼药(300573.SZ)：37个产品继续纳入国家医保目录
智通财经 · 11-29
兴齐眼药(300573.SZ)：37个产品继续纳入国家医保目录
兴齐眼药：德邦证券、富国基金等多家机构于11月28日调研我司
证券之星 · 11-29
兴齐眼药：德邦证券、富国基金等多家机构于11月28日调研我司
兴齐眼药（300573）11月26日主力资金净买入1729.07万元
证券之星 · 11-27
兴齐眼药（300573）11月26日主力资金净买入1729.07万元
11月22日兴齐眼药跌5.35%，富国天博创新主题混合基金重仓该股
证券之星 · 11-22
11月22日兴齐眼药跌5.35%，富国天博创新主题混合基金重仓该股
【企业动态】兴齐眼药新增1件法院诉讼，案由为机动车交通事故责任纠纷
证券之星 · 11-21
【企业动态】兴齐眼药新增1件法院诉讼，案由为机动车交通事故责任纠纷
兴齐眼药：盐酸利多卡因眼用凝胶获临床试验批准
美港电讯 · 11-18
兴齐眼药：盐酸利多卡因眼用凝胶获临床试验批准
兴齐眼药(300573.SZ)：盐酸利多卡因眼用凝胶获临床试验批准
智通财经 · 11-18
兴齐眼药(300573.SZ)：盐酸利多卡因眼用凝胶获临床试验批准
兴齐眼药(300573.SZ)：环孢素滴眼液(Ⅱ)上市后临床试验取得Ⅳ期临床研究报告
智通财经 · 11-12
兴齐眼药(300573.SZ)：环孢素滴眼液(Ⅱ)上市后临床试验取得Ⅳ期临床研究报告
兴齐眼药(300573.SZ)：盐酸奥洛他定滴眼液获药品注册证书
智通财经 · 11-11
兴齐眼药(300573.SZ)：盐酸奥洛他定滴眼液获药品注册证书
兴齐眼药（300573）82.44万股限售股将于11月11日解禁，占总股本0.47%
证券之星 · 11-11
兴齐眼药（300573）82.44万股限售股将于11月11日解禁，占总股本0.47%
开源证券：给予兴齐眼药买入评级
证券之星 · 11-04
开源证券：给予兴齐眼药买入评级
11月4日兴齐眼药涨7.05%，富国天博创新主题混合基金重仓该股
证券之星 · 11-04
11月4日兴齐眼药涨7.05%，富国天博创新主题混合基金重仓该股
兴齐眼药：11月1日接受机构调研，包括知名机构正心谷资本的多家机构参与
证券之星 · 11-02
兴齐眼药：11月1日接受机构调研，包括知名机构正心谷资本的多家机构参与
兴齐眼药最新公告：撤回马来酸噻吗洛尔滴眼液注册申请
证券之星 · 10-30
兴齐眼药最新公告：撤回马来酸噻吗洛尔滴眼液注册申请
暂无数据
公司概况
公司名称：
沈阳兴齐眼药股份有限公司
所属行业：
医药制造业
上市日期：
2016-12-08
主营业务：
沈阳兴齐眼药股份有限公司专注于眼科药物领域,是一家主要从事眼科药物研发、生产、销售的专业企业,主要产品是眼科处方药物。以“兹润”、“速高捷”、“迪友”、“迪非”、“兹养”等产品为代表的眼用制剂产品已在行业内树立了良好的品牌声誉。公司多项产品被认定为国家重点新产品、省名牌产品、省优秀新产品、省质量名优产品。
发行价格：
5.16
{"stockData":{"symbol":"300573","market":"SZ","secType":"STK","nameCN":"兴齐眼药","latestPrice":77.63,"timestamp":1734591810000,"preClose":78.47,"halted":0,"volume":4074146,"delay":0,"floatShares":135000000,"shares":175000000,"eps":1.9885,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.84,"latestTime":"12-19 15:00:00","open":77.85,"high":78.36,"low":77.2,"amount":317000000,"amplitude":0.0148,"askPrice":77.63,"askSize":25,"bidPrice":77.62,"bidSize":118,"shortable":0,"etf":0,"ttmEps":1.9885,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"adjPreClose":78.47,"symbolType":"stock","openAndCloseTimeList":[[1734571800000,1734579000000],[1734584400000,1734591600000]],"highLimit":86.32,"lowLimit":70.62,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":175249247,"pbRate":8.45,"roa":"--","roe":"16.03%","epsLYR":1.93,"committee":0.490654,"marketValue":13605000000,"floatMarketCap":10466000000,"peRate":39.039477,"changeRate":-0.0107,"turnoverRate":0.0302,"status":1},"requestUrl":"/m/hq/s/300573/tweets","defaultTab":"tweets","newsList":[{"id":"2492078789","title":"兴齐眼药：公司持续聚焦眼科领域，坚持专业化发展道路，暂无眼科相关的医疗器械研发、生产和销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2492078789","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492078789?lang=zh_cn&edition=full","pubTime":"2024-12-18 20:00","pubTimestamp":1734523216,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)12月18日在投资者关系平台上答复投资者关心的问题。投资者：董秘你好，公司有无眼科相关的医疗器械研发、生产和销售兴齐眼药董秘：尊敬的投资者您好，公司持续聚焦眼科领域，坚持专业化发展道路，暂无眼科相关的医疗器械研发、生产和销售。未来公司将根据自身发展情况结合公司战略，制定产业延伸和协同发展策略。感谢您的关注。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121800035359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","09997","300573","BK1574","BK0239","BK1222","BK1583","BK1100","09996","159883"],"gpt_icon":0},{"id":"2492981671","title":"兴齐眼药（300573）12月16日主力资金净卖出1.20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492981671","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492981671?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:23","pubTimestamp":1734398619,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月16日收盘，兴齐眼药报收于80.88元，下跌3.91%，换手率7.34%，成交量9.9万手，成交额8.06亿元。12月16日的资金流向数据方面，主力资金净流出1.2亿元，占总成交额14.94%，游资资金净流入8849.34万元，占总成交额10.98%，散户资金净流入3190.73万元，占总成交额3.96%。融券方面，融券卖出4800.0股，融券偿还1.2万股，融券余量3.72万股，融券余额300.87万元。兴齐眼药主营业务：眼科药物研发、生产、销售的专业企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121700008959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0177","BK0239"],"gpt_icon":0},{"id":"2489407122","title":"兴齐眼药：12月6日接受机构调研，北京博润银泰、明世伙伴等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2489407122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489407122?lang=zh_cn&edition=full","pubTime":"2024-12-06 18:33","pubTimestamp":1733481211,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年12月6日兴齐眼药发布公告称公司于2024年12月6日接受机构调研，北京博润银泰尚方建 陈嘉进、明世伙伴何德建、东北证券白雨 李屹昆 邹锦程 宋卓 张鑫 胡博、北京融盛私募石宇、北京英安私募朱光宇 石海吉、财智聚宋承东 宋海文、大连航天半岛高新创投刘悦丰、东北证券研究所古翰羲、景星资产冯伟、天融资本柏平、众妙资本林红霞参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600034857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2488532613","title":"【机构调研记录】永赢基金调研兴齐眼药、新锐股份等15只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2488532613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488532613?lang=zh_cn&edition=full","pubTime":"2024-12-02 08:02","pubTimestamp":1733097767,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月29日披露的机构调研信息，永赢基金近期对15家上市公司进行了调研，相关名单如下：1）兴齐眼药 （永赢基金参与公司特定对象调研）兴齐眼药2024年三季报显示，公司主营收入14.39亿元，同比上升30.27%；归母净利润2.91亿元，同比上升59.47%；扣非净利润2.9亿元，同比上升63.31%；其中2024年第三季度，公司单季度主营收入5.47亿元，同比上升3","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200001041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","688257","BK0233","BK0239","300573"],"gpt_icon":0},{"id":"2488613312","title":"【机构调研记录】国海富兰克林基金调研兴齐眼药、科达制造","url":"https://stock-news.laohu8.com/highlight/detail?id=2488613312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488613312?lang=zh_cn&edition=full","pubTime":"2024-12-02 08:02","pubTimestamp":1733097728,"startTime":"0","endTime":"0","summary":"2）科达制造 个股亮点：公司GDR已经于2022-07-28成功上市。；公司陶瓷机械+清洁能源装备；公司在一带一路沿线地区开展了陶瓷机械、建筑陶瓷业务，其中在“一带一路”沿线业务涉及东南亚、中东、非洲等地区国海富兰克林基金成立于2004年，截至目前，资产管理规模808.27亿元，排名68/208；资产管理规模558.28亿元，排名66/208；管理公募基金数91只，排名71/208；旗下公募基金经理16人，排名82/208。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200001000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0251","300573","BK0070","BK0239","600499","BK0188","BK0155"],"gpt_icon":0},{"id":"2488761803","title":"【机构调研记录】前海开源基金调研兴齐眼药、肇民科技等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2488761803","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488761803?lang=zh_cn&edition=full","pubTime":"2024-12-02 08:01","pubTimestamp":1733097696,"startTime":"0","endTime":"0","summary":"2）肇民科技 个股亮点：公司与客户共同开发人形机器人精密零部件新品。；公司的静脉补充维生素用药涉及12种复合维生素产品前海开源基金成立于2013年，截至目前，资产管理规模976.53亿元，排名62/208；资产管理规模825.86亿元，排名54/208；管理公募基金数165只，排名41/208；旗下公募基金经理32人，排名39/208。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200000974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177","BK0220","301000"],"gpt_icon":0},{"id":"2487558291","title":"兴齐眼药(300573.SZ)：37个产品继续纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2487558291","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487558291?lang=zh_cn&edition=full","pubTime":"2024-11-29 16:15","pubTimestamp":1732868120,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)公告，公司共有37个产品继续纳入国家医保目录，其中甲类8个，乙类29个。环孢素滴眼液(Ⅱ)、复方电解质眼内冲洗液、玻璃酸钠滴眼液等多种产品继续纳入《国家医保目录》;本次公司没有产品退出《国家医保目录》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0177","BK0239","300573"],"gpt_icon":0},{"id":"2487858503","title":"兴齐眼药：德邦证券、富国基金等多家机构于11月28日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2487858503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487858503?lang=zh_cn&edition=full","pubTime":"2024-11-29 15:03","pubTimestamp":1732863825,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月29日兴齐眼药发布公告称德邦证券吴明华、富国基金赵伟、信达澳亚刘颢然、永赢基金单林、国海富兰克林基金刘牧、前海开源基金于成龙于2024年11月28日调研我司。公司低浓度硫酸阿托品滴眼液是处方药物，患者可通过具有资质的公立医院、民营医院、视光中心等机构进行处方购买。根据国家药监局相关规定,医疗机构制剂是指医疗机构根据本单位临床需要经批准而配制、自用的固定处方制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112900016714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","161027","BK0177","BK0239"],"gpt_icon":0},{"id":"2486868102","title":"兴齐眼药（300573）11月26日主力资金净买入1729.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486868102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486868102?lang=zh_cn&edition=full","pubTime":"2024-11-27 09:14","pubTimestamp":1732670060,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月26日收盘，兴齐眼药报收于81.42元，上涨3.0%，换手率5.34%，成交量7.19万手，成交额5.9亿元。11月26日的资金流向数据方面，主力资金净流入1729.07万元，占总成交额2.93%，游资资金净流出1773.52万元，占总成交额3.0%，散户资金净流入44.45万元，占总成交额0.08%。融券方面，融券卖出5600.0股，融券偿还1.25万股，融券余量1.91万股，融券余额155.51万元。兴齐眼药主营业务：眼科药物研发、生产、销售的专业企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112700008446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2485235847","title":"11月22日兴齐眼药跌5.35%，富国天博创新主题混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485235847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485235847?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:31","pubTimestamp":1732264294,"startTime":"0","endTime":"0","summary":"证券之星消息，11月22日兴齐眼药跌5.35%，收盘报80.3元，换手率4.47%，成交量6.03万手，成交额4.97亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共35家，其中持有数量最多的公募基金为富国天博创新主题混合。富国天博创新主题混合目前规模为18.35亿元，最新净值1.6926，较上一交易日下跌0.43%，近一年下跌3.76%。富国天博创新主题混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200026121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2485174439","title":"【企业动态】兴齐眼药新增1件法院诉讼，案由为机动车交通事故责任纠纷","url":"https://stock-news.laohu8.com/highlight/detail?id=2485174439","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485174439?lang=zh_cn&edition=full","pubTime":"2024-11-21 06:20","pubTimestamp":1732141226,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，11月20日兴齐眼药（300573）新增1件法院诉讼如下：案号：（2024）辽0106民初23538号法院：沈阳市铁西区人民法院案由：机动车交通事故责任纠纷原告：马某某被告：侯某某、中国平安财产保险股份有限公司辽宁分公司、沈阳兴齐眼药股份有限公司案件类型：民事立案日期：2024年11月20日数据来源：企查查以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100004007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0177","BK0239"],"gpt_icon":0},{"id":"2484552614","title":"兴齐眼药：盐酸利多卡因眼用凝胶获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484552614","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484552614?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:46","pubTimestamp":1731916010,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["03347","BK1583","BK0239","BK1141","300573","BK1576","BK0177"],"gpt_icon":0},{"id":"2484614919","title":"兴齐眼药(300573.SZ)：盐酸利多卡因眼用凝胶获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484614919","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484614919?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:46","pubTimestamp":1731916004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)公告，公司收到国家药品监督管理局签发的关于盐酸利多卡因眼用凝胶的《药物临床试验批准通知书》，盐酸利多卡因眼用凝胶适应症为适用于眼科操作中的眼表麻醉。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0177","03347","BK0239","BK1141","BK1583","300573","BK1576"],"gpt_icon":0},{"id":"2482268927","title":"兴齐眼药(300573.SZ)：环孢素滴眼液(Ⅱ)上市后临床试验取得Ⅳ期临床研究报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2482268927","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482268927?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:44","pubTimestamp":1731397454,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药 发布公告，公司的产品环孢素滴眼液(Ⅱ)，近期获得了“环孢素滴眼液(Ⅱ)治疗干眼的安全性和有效性多中心临床研究”的Ⅳ期临床研究报告。该研究是一项多中心、前瞻性临床试验，1999例受试者经过了为期24周的用药观察，评价环孢素滴眼液(Ⅱ)用于干眼患者的安全性和有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0177","03347","BK0239","300573","BK1141","BK1583","BK1576"],"gpt_icon":0},{"id":"2482270522","title":"兴齐眼药(300573.SZ)：盐酸奥洛他定滴眼液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482270522","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482270522?lang=zh_cn&edition=full","pubTime":"2024-11-11 17:14","pubTimestamp":1731316440,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)公告，公司收到国家药品监督管理局核准签发的盐酸奥洛他定滴眼液《药品注册证书》。公司本次获批的盐酸奥洛他定滴眼液为多剂量产品，临床适应症为用于治疗过敏性结膜炎相关的眼痒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2482219405","title":"兴齐眼药（300573）82.44万股限售股将于11月11日解禁，占总股本0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482219405","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482219405?lang=zh_cn&edition=full","pubTime":"2024-11-11 08:02","pubTimestamp":1731283372,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，兴齐眼药于11月11日将有82.44万股限售股份解禁，为公司股权激励一般股份，占公司总股本0.47%。本次解禁后，公司还有4043.6万股限售股份，占总股本23.18%。兴齐眼药主营业务：眼科药物研发、生产、销售的专业企业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111100001076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0177","BK0239"],"gpt_icon":0},{"id":"2480586603","title":"开源证券：给予兴齐眼药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480586603","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480586603?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:10","pubTimestamp":1730729438,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,刘艺近期对兴齐眼药进行研究并发布了研究报告《公司信息更新报告：静待低浓度阿托品加速放量，眼科产品持续完善》，本报告对兴齐眼药给出买入评级，当前股价为89.49元。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为180.23。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400031683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300573"],"gpt_icon":0},{"id":"2480373234","title":"11月4日兴齐眼药涨7.05%，富国天博创新主题混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480373234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480373234?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:21","pubTimestamp":1730708518,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日兴齐眼药涨7.05%，收盘报89.49元，换手率8.74%，成交量11.72万手，成交额10.3亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共35家，其中持有数量最多的公募基金为富国天博创新主题混合。富国天博创新主题混合目前规模为18.35亿元，最新净值1.6842，较上一交易日下跌0.49%，近一年下跌4.89%。富国天博创新主题混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400020222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2480841960","title":"兴齐眼药：11月1日接受机构调研，包括知名机构正心谷资本的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2480841960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480841960?lang=zh_cn&edition=full","pubTime":"2024-11-02 17:31","pubTimestamp":1730539876,"startTime":"0","endTime":"0","summary":"答：公司 0.01%低浓度硫酸阿托品滴眼液上市后，根据我们当时的查询结果，共有 9 家医疗机构获得医疗机构制剂批件。截至目前，上述医疗机构制剂批件还剩余 6家，其中有 3家适应症为散瞳和睫状肌麻痹，而且这些医疗机构制剂仅限在本医疗机构范围内使用，受众人群有限。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110200006953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2479222541","title":"兴齐眼药最新公告：撤回马来酸噻吗洛尔滴眼液注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2479222541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479222541?lang=zh_cn&edition=full","pubTime":"2024-10-30 16:51","pubTimestamp":1730278297,"startTime":"0","endTime":"0","summary":"兴齐眼药公告，公司收到国家药监局核准签发的《药品注册申请终止通知书》，同意公司撤回马来酸噻吗洛尔滴眼液的注册申请。公司于2023年3月递交该药品仿制药上市注册申请并获受理，因政策法规变更等因素影响，需进一步完善申报资料，经审慎研究，公司决定主动撤回本次补充申请。该药品注册申请的主动撤回并终止对已上市产品及公司研发工作无重大影响。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000029626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0177","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-12-08","address":"辽宁省沈阳市浑南区中国(辽宁)自由贸易试验区沈阳片区新运河路25号","stockEarnings":[{"period":"1week","weight":-0.0882},{"period":"1month","weight":-0.095},{"period":"3month","weight":0.1471},{"period":"6month","weight":-0.5439},{"period":"1year","weight":-0.3462},{"period":"ytd","weight":-0.394}],"companyName":"沈阳兴齐眼药股份有限公司","boardCode":"AI0027","perCapita":"3496股","boardName":"医药制造业","registeredCapital":"17524万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":" 沈阳兴齐眼药股份有限公司专注于眼科药物领域,是一家主要从事眼科药物研发、生产、销售的专业企业,主要产品是眼科处方药物。以“兹润”、“速高捷”、“迪友”、“迪非”、“兹养”等产品为代表的眼用制剂产品已在行业内树立了良好的品牌声誉。公司多项产品被认定为国家重点新产品、省名牌产品、省优秀新产品、省质量名优产品。","serverTime":1734632858481,"listedPrice":5.16,"stockholders":"38554人(较上一季度增加108.98%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"兴齐眼药,300573,兴齐眼药股票,兴齐眼药股票老虎,兴齐眼药股票老虎国际,兴齐眼药行情,兴齐眼药股票行情,兴齐眼药股价,兴齐眼药股市,兴齐眼药股票价格,兴齐眼药股票交易,兴齐眼药股票购买,兴齐眼药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}